INS and type 1 diabetes mellitus: Using this technique PBMC proliferative cell responses were assessed in sequential samples from autoantibody-negative children at high risk of type 1 diabetes recruited into an oral insulin trial (Pre-POINT) (77); children were administered placebo or assigned in blocks to receive insulin at escalating doses from 2.5–67.5 mg.